Sugi Predict

Sugi Predict / Targets / ITGB2

ITGB2

Integrin beta-2 · P05107 · ITGB2 on Sugi Atlas →

36,110 patent compounds predicted against ITGB2, 20,159 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL879320 SCHEMBL879320 1.00 20/20
SCHEMBL879361 SCHEMBL879361 1.00 20/20
SCHEMBL879369 SCHEMBL879369 1.00 20/20
SCHEMBL879397 SCHEMBL879397 0.78 20/20
SCHEMBL879362 SCHEMBL879362 0.77 20/20
SCHEMBL879396 SCHEMBL879396 0.77 20/20
SCHEMBL879360 SCHEMBL879360 0.76 20/20
SCHEMBL879319 SCHEMBL879319 0.76 20/20
SCHEMBL879334 SCHEMBL879334 0.69 20/20
SCHEMBL879338 SCHEMBL879338 0.69 20/20
SCHEMBL879401 SCHEMBL879401 0.63 20/20
SCHEMBL879391 SCHEMBL879391 0.57 20/20
SCHEMBL879351 SCHEMBL879351 0.57 20/20
SCHEMBL879343 SCHEMBL879343 0.56 20/20
SCHEMBL879340 SCHEMBL879340 0.53 20/20
SCHEMBL879387 SCHEMBL879387 0.52 20/20
SCHEMBL879390 SCHEMBL879390 0.52 20/20
SCHEMBL879341 SCHEMBL879341 0.52 20/20
SCHEMBL879404 SCHEMBL879404 0.52 20/20
SCHEMBL879324 SCHEMBL879324 0.52 20/20

Clinical trials — most relevant to ITGB2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Outcomes of ICSI Cycles With and Without Letrozole PHASE4UNKNOWN
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease PHASE2UNKNOWN
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption PHASE1COMPLETED
A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors EARLY_PHASE1RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer nanUNKNOWN
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Clinical Pattern of Glanzemnn Thrombathenia in Children Attending Assiut University Children Hospital nanNOT_YET_RECRUITING
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer nanUNKNOWN
Clinical Study of 18F-FAPI-RGD in Breast Tumors nanCOMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ITGB2 binder may also engage these)

ProteinNameSimilarity
P32592 — 1.000 P32592 →
P11835 — 1.000 P11835 →
Q6ECI6 — 1.000 Q6ECI6 →
P53714 — 1.000 P53714 →
Q2VJ42 — 1.000 Q2VJ42 →
Q5VI41 — 1.000 Q5VI41 →
P12607 — 0.999 P12607 →
ITGB1 Integrin beta-1 0.997 landscape →
Q5RCA9 — 0.997 Q5RCA9 →
Q3UV74 — 0.995 Q3UV74 →
P09055 — 0.994 P09055 →
P07228 — 0.994 P07228 →
P49134 — 0.994 P49134 →
P11584 — 0.993 P11584 →
Q9GLP0 — 0.993 Q9GLP0 →
P53713 — 0.993 P53713 →
B0FYY4 — 0.992 B0FYY4 →
Q27874 — 0.992 Q27874 →
ITGB4 Integrin beta-4 0.992 landscape →
P12606 — 0.990 P12606 →
P53712 — 0.990 P53712 →
Q27591 — 0.990 Q27591 →
A5Z1X6 — 0.990 A5Z1X6 →
A2A863 — 0.989 A2A863 →
Q64632 — 0.989 Q64632 →
P26011 — 0.987 P26011 →
MMP14 Matrix metalloproteinase-14 0.985 landscape →
O88917 — 0.985 O88917 →
P50757 — 0.985 P50757 →
O77633 — 0.984 O77633 →